4,8-dichloropyrrolo[1,2-a]quinoxaline | 160657-05-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4,8-dichloropyrrolo[1,2-a]quinoxaline
• CAS: 160657-05-6
• 化学式: C₁₁H₆Cl₂N₂
• 分子量: 237.088
• InChiKey: ZEGUHRWWZOMQGV-UHFFFAOYSA-N

物化性质

• 沸点：
  329.4±42.0 °C(Predicted)
• 密度：
  1.49±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  17.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-氨基-5-二乙基氨基戊烷 、 4,8-dichloropyrrolo[1,2-a]quinoxaline 反应 4.0h， 以79%的产率得到4-N-(8-chloropyrrolo[1,2-a]quinoxalin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine
  参考文献：
  名称：

  Synthesis, Antimalarial Activity, and Molecular Modeling of New Pyrrolo[1,2-a]quinoxalines, Bispyrrolo[1,2-a]quinoxalines, Bispyrido[3,2-e]pyrrolo[1,2-a]pyrazines, and Bispyrrolo[1,2-a]thieno[3,2-e]pyrazines

  摘要：

  Three pyrrolo[1,2-a]quinoxalines, 15 bispyrrolo[1,2-a]quinoxalines, bispyrido[3,2-e]pyrrolo[1,2-a]pyrazines, and bispyrrolo[1,2-a]thieno[3,2-e]pyrazines were synthesized from various substituted nitroanilines or nitropyridines and tested for their in vitro activity upon the erythrocytic development of Plasmodium falciparum strains with different chloroquine-resistance status. Bispyrrolo[1,2-a]quinoxalines showed superior antimalarial. activity with respect to monopyrrolo[1,2-a]quinoxalines. The best activity was observed with bispyrrolo[1,2-a]quinoxalines linked by a bis(3-aminopropyl)piperazine. Moreover, it was observed that the presence of a methoxy group on the pyrrolo[1,2-a]quinoxaline nucleus increased the pharmacological activity. Drug effects upon beta-hematin formation were assayed and showed similar or higher inhibitory activities than CQ. A possible mechanism of interaction implicating binding of pyrroloquinoxalines to beta-hematin was supported by molecular modeling.

  DOI：

  10.1021/jm0310840
• 作为产物：
  描述：

  1-(5-chloro-2-nitrophenyl)-1H-pyrrole 在 bismuth(III) chloride 、 sodium tetrahydroborate 、 三氯氧磷 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 10.0h， 生成 4,8-dichloropyrrolo[1,2-a]quinoxaline
  参考文献：
  名称：

  Synthesis, Antimalarial Activity, and Molecular Modeling of New Pyrrolo[1,2-a]quinoxalines, Bispyrrolo[1,2-a]quinoxalines, Bispyrido[3,2-e]pyrrolo[1,2-a]pyrazines, and Bispyrrolo[1,2-a]thieno[3,2-e]pyrazines

  摘要：

  Three pyrrolo[1,2-a]quinoxalines, 15 bispyrrolo[1,2-a]quinoxalines, bispyrido[3,2-e]pyrrolo[1,2-a]pyrazines, and bispyrrolo[1,2-a]thieno[3,2-e]pyrazines were synthesized from various substituted nitroanilines or nitropyridines and tested for their in vitro activity upon the erythrocytic development of Plasmodium falciparum strains with different chloroquine-resistance status. Bispyrrolo[1,2-a]quinoxalines showed superior antimalarial. activity with respect to monopyrrolo[1,2-a]quinoxalines. The best activity was observed with bispyrrolo[1,2-a]quinoxalines linked by a bis(3-aminopropyl)piperazine. Moreover, it was observed that the presence of a methoxy group on the pyrrolo[1,2-a]quinoxaline nucleus increased the pharmacological activity. Drug effects upon beta-hematin formation were assayed and showed similar or higher inhibitory activities than CQ. A possible mechanism of interaction implicating binding of pyrroloquinoxalines to beta-hematin was supported by molecular modeling.

  DOI：

  10.1021/jm0310840

文献信息

• HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE
  申请人：Borchardt Allen

  公开号：US20110257137A1

  公开（公告）日：2011-10-20

  The present invention relates to compounds and methods which may be useful as inhibitors of H 1 R and/or H 4 R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

  本发明涉及化合物和方法，可用作H1R和/或H4R的抑制剂，用于治疗或预防炎症、自身免疫、过敏和眼部疾病。
• Dérivés de pyrrolopyrazines à activité 5-HT3
  申请人：ADIR ET COMPAGNIE

  公开号：EP0623620A1

  公开（公告）日：1994-11-09

  La présente invention concerne les composés de formule (I) : dans laquelle A et R₁ sont tels que définis dans la description. Médicaments.

  本发明涉及式（I）化合物： 其中 A 和 R₁ 如描述中所定义。 药物。
• Novel and Selective Partial Agonists of 5-HT₃ Receptors. 2. Synthesis and Biological Evaluation of Piperazinopyridopyrrolopyrazines, Piperazinopyrroloquinoxalines, and Piperazinopyridopyrroloquinoxalines
  作者：Hervé Prunier、Sylvain Rault、Jean-Charles Lancelot、Max Robba、Pierre Renard、Philippe Delagrange、Bruno Pfeiffer、Daniel-Henri Caignard、René Misslin、Béatrice Guardiola-Lemaitre, and、Michel Hamon

  DOI：10.1021/jm960501o

  日期：1997.6.1

  In continuation of our previous work on piperazinopyrrolothienopyrazine derivatives, three series of piperazinopyridopyrrolopyrazines, piperazinopyrroloquinoxalines, and piperazinopyridopyrrolaquinoxalines were prepared and evaluated as 5-HT3 receptor ligands. The chemical modifications performed within these new series led to structure-activity relationships regarding both high affinity and selectivity for the 5-HT3 receptors that are in agreement with those established previously for the pyrrolothienopyrazine series. The best compound (8a) obtained in these new series is in the picomolar range of affinity for 5-HT3 receptors with a selectivity higher than 10(6). Four of the high-affinity 5-HT3 ligands (8a, 15a,b, and 16d) were selected in both the pyridopyrrolopyrazine and the pyrroloquinoxaline series and were characterized in vitro and in vivo as agonists or partial agonists. Compound 8a was also evaluated in the light/dark test where it showed potential anxiolytic-like activity at very low doses per os.
• US5599812A
  申请人：——

  公开号：US5599812A

  公开（公告）日：1997-02-04
• [EN] HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE RÉCEPTEURS DE L'HISTAMINE DESTINÉS AU TRAITEMENT DE MALADIE
  申请人：KALYPSYS INC

  公开号：WO2011112731A2

  公开（公告）日：2011-09-15

  The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.